|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Therapeutic developments in migraine have come by targeting the trigeminovascular system, with the most-recent being the proof-of-principle study of calcitonin gene-related peptide (CGRP) receptor antagonists in acute migraine.
|
17141570 |
2007 |
|
Migraine Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results demonstrate that RAMP1 is functionally rate limiting for CGRP receptor activity in the trigeminal ganglion, which raises the possibility that elevated RAMP1 might sensitize some individuals to CGRP actions in migraine.
|
17344407 |
2007 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We have previously demonstrated that nestin/hRAMP1 mice display a light-aversive behavior that is greatly enhanced by CGRP and blocked by a CGRP receptor antagonist used to treat migraine.
|
19607849 |
2010 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The CGRP receptor antagonists telcagepant and olcegepant (BIBN4096BS) have demonstrated clinical efficacy in the treatment of migraine and there is now a need to better understand how these molecules interact with the receptor.
|
20188075 |
2010 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent advances in the biology of the cerebellum indicate that there may be a role in nociception; hence a target of the recently discovered CGRP receptor antagonists that have demonstrated improvement in migraine pain and associated symptoms could be cerebellar CGRP receptors.
|
21040789 |
2011 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Consequently, genes involved in CGRP synthesis or CGRP receptor genes may play a role in migraine and/or increase susceptibility.
|
23237777 |
2013 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Calcitonin-gene-related peptide (CGRP) is a neuropeptide involved in migraine pathology, where there is elevated release of CGRP during migraine attacks and CGRP receptor antagonists have antimigraine efficacy.
|
23917876 |
2013 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinical trials carried out during the past decade have proved that CGRP receptor antagonists are effective for treating migraine, and antibodies to the receptor and CGRP are currently under investigation.
|
25340934 |
2015 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Conclusion Our data show an unexpected 'positive' role for the endogenous pro-nociceptive migraine mediator CGRP, suggesting more careful examination of migraine prophylaxis strategy based on CGRP antagonism although it should be noted that homocysteine induced apoptosis in primary neuronal cell culture might not necessarily reproduce all the features of cell loss in the living organism.
|
27884929 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Discussion Provocation experiments demonstrated a heterogeneous CGRP migraine response in migraine patients.
|
27940880 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
However, a peripheral site of action is indicated by the ability of intravenous CGRP to trigger migraine in humans and the efficacy of CGRP receptor antagonists that evidently do no penetrate the CNS in effective amounts.
|
28053042 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, we performed a meta-analysis to evaluate the efficacy and safety of CGRP mAbs for preventive treatment of migraine.
|
28129635 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CGRP receptor antagonists, including olcegepant (BIBN4096BS) and telcagepant (MK-0974), can treat migraine.
|
28165287 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Understanding the biology of migraine through careful bench-based research has led to major classes of therapeutics being identified: triptans, serotonin 5-HT<sub>1B/1D</sub> receptor agonists; gepants, calcitonin gene-related peptide (CGRP) receptor antagonists; ditans, 5-HT<sub>1F</sub> receptor agonists, CGRP mechanisms monoclonal antibodies; and glurants, mGlu<sub>5</sub> modulators; with the promise of more to come.
|
28179394 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The recent identification of the CGRP-responsive calcitonin receptor/RAMP1 complex (AMY<sub>1</sub> receptor - amylin subtype 1 receptor) in the trigeminovascular system warrants a deeper consideration of the molecular identity of CGRP receptor(s) involved in the pathophysiology, and thus potential treatment of migraine.
|
28233915 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We will further discuss the therapeutic agents which have appeared in the most recent years for migraine care, from calcitonin gene-related peptide (CGRP) receptor antagonists, gepants; through serotonin 5-HT<sub>1F</sub> receptor agonists, ditans, and CGRP or CGRP receptor monoclonal antibodies to invasive and non-invasive neuromodulation techniques.
|
28321564 |
2017 |
|
Migraine Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Methods Following sumatriptan priming to model MOH, rats were hyper-responsive to environmental stress, demonstrating delayed cephalic and extracephalic allodynia and increased levels of CGRP in the jugular blood, consistent with commonly observed clinical outcomes during migraine.
|
28376659 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies to calcitonin gene-related peptide and its receptor (CGRP-mAbs) appear more promising for migraine because of considerably better effect and safety profiles.
|
28389966 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Given the clear involvement of the neuropeptide CGRP in migraine and the emerging evidence for other peptides, it seems likely that neuropeptides may help "awaken" the senses and contribute to the heightened sensory state of migraine.
|
28485842 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibitor of AChE neostigmine did not change the firing <i>per se</i> but induced nociceptive activity, sensitive to d-tubocurarine, after pretreatment of meninges with the migraine mediator CGRP.
|
28496430 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
ECL2 is fundamental for ligand-induced activation of the calcitonin gene related peptide (CGRP) receptor, a family B GPCR implicated in migraine and heart disease.
|
28572046 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we will discuss the growing body of clinical trials studying CGRP-targeted therapies for migraine and cluster headache.
|
28644160 |
2018 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Monoclonal antibodies against CGRP or the CGRP receptor have a longer duration of action and have been investigated for migraine prevention.
|
28653227 |
2017 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Recognizing the role of CGRP and CGRP receptors in migraine and its treatment.
|
29020807 |
2019 |
|
Migraine Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Functional blockade of CGRP, which involves either CGRP receptor antagonists or monoclonal antibodies (mAbs) to CGRP or its receptor, has recently shown clinical efficacy in migraine management.
|
29116598 |
2017 |